BHVN

Biohaven Ltd

15.42

Oct 30 • 3:59 PM ET -1.07 (-6.49%)

15.41

Aftermarket • 7:30 PM ET -0.01 (-0.06%)

Healthcare Biotechnology USA Mid NYSE

Oct 29, 6:16 PMBiohaven Ltd inks SK Biopharmaceuticals and Ono licensing deals for up to $500M cash and reports fiscal Q3 2026 EPS $-0.86, revenue $0, missing estimates

Peers: XENE PRAX RAPP PTCT IMVT SRRK DRUG ARGX BIIB NBIX

| Held by: XBI IWM IWO VXF IBB SCHA VTWO FESM PINK VHT

Scroll to Statements

Index	RUT
Market Cap	2.33B
Enterprise Value	2.47B
Income	-542.68M
Sales	0.00M
Book/sh	-0.65
Cash/sh	1.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	274
IPO	May 04, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	14.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.05
Current Ratio	3.05
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-3.86
EPS next Y	-2.46
EPS next Q	0.07
EPS this Y	63.68%
EPS next Y	1.42%
EPS next 5Y	32.79%
EPS past 3/5Y	6.37% -30.08%
Sales past 3/5Y	- -
EPS Y/Y TTM	49.16%
Sales Y/Y TTM	-
EPS Q/Q	47.78%
Sales Q/Q	-
Earnings	Oct 29 AMC
EPS/Sales Surpr.	-9.79% -100.00%

Insider Own	14.89%
Insider Trans	0.00%
Inst Own	90.89%
Inst Trans	-5.50%
ROA	-161.32%
ROE	-799.46%
ROIC	-274.84%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	19.55%
SMA50	13.19%
SMA200	26.12%
Trades

Shs Outstand	151.06M
Shs Float	128.57M
Short Float	13.92%
Short Ratio	5.76
Short Interest	17.90M
52W High	18.57 -16.94%
52W Low	7.48 106.15%
Volatility	7.28% 6.89%
ATR (14)	1.10
RSI (14)	61.06
Beta	3.18
Rel Volume	1.02
Avg Volume	3.11M
Volume	3,164,755

Perf Week	11.10%
Perf Month	17.35%
Perf Quarter	15.33%
Perf Half Y	60.12%
Perf YTD	36.58%
Perf Year	-11.33%
Perf 3Y	-44.19%
Perf 5Y	-
Perf 10Y	-
Recom	1.71
Target Price	25.67
Prev Close	16.49
Price	15.42
Change %	-6.49%

Consensus

Buy

Avg. Price Target

$25.67

Implied Upside

+66.5%

Analysts13incl. previous ratings

Rating Distribution8 Buy · 4 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 08, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$19	+23.2%
Jun 29, 2026	Downgrade	BBofA Securities	Neutral → Underperform	$11	-28.7%
Apr 13, 2026	Initiated	CCanaccord Genuity	Buy	$21	+36.2%
Feb 06, 2026	Initiated	GGoldman	Buy	$23	+49.2%
Jan 21, 2026	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform	$22	+42.7%
Dec 03, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral	$11	-28.7%
Nov 26, 2025	Downgrade	UUBS	Buy → Neutral	$11	-28.7%
Nov 06, 2025	Downgrade	BBernstein	Outperform → Mkt Perform	$9	-41.6%
Nov 05, 2025	Downgrade	BBofA Securities	Buy → Neutral	$10	-35.1%
Sep 17, 2025	Initiated	CCitigroup	Buy	$28	+81.6%
Sep 03, 2025	Initiated	RRaymond James	Strong Buy	$75	+386.4%
May 19, 2025	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$21	+36.2%
Feb 11, 2025	Initiated	DDeutsche Bank	Buy	$65	+321.5%
Sep 16, 2024	Initiated	JJefferies	Buy	$57	+269.6%
Sep 04, 2024	Initiated	BBernstein	Outperform	$55	+256.7%
Jul 24, 2024	Initiated	MMorgan Stanley	Overweight	$58	+276.1%
Feb 16, 2024	Initiated	RRBC Capital Mkts	Outperform	$62	+302.1%
Feb 06, 2024	Initiated	UUBS	Buy	$59	+282.6%
Dec 22, 2023	Initiated	HH.C. Wainwright	Buy	$50	+224.3%
Dec 08, 2023	Initiated	RRobert W. Baird	Outperform	$58	+276.1%

Oct-29-26 04:02PM	Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results (PR Newswire) +6.25% -6.49%
Oct-26-26 07:30AM	Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy (PR Newswire)
Oct-22-26 01:29PM	Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again (Barrons.com) +25.02%
12:24PM	Biohavens previously rejected rare disease drug to get fresh FDA review (BioPharma Dive)
09:27AM	BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia (Stocktwits)
07:43AM	Loading…
07:43AM	Biohaven stock surges 25% on FDA acceptance of drug filing (Investing.com)
Oct-09-26 09:12PM	Stocktwits Biotech Dealmaker Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights (Stocktwits)
05:00AM	Biohaven partners with Ono in $100m IgG degrader deal (Pharmaceutical Technology)
Oct-08-26 04:00AM	Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease (PR Newswire)
Oct-02-26 09:54AM	Roches AI lab; Biohavens pivotal pause (Pharma Voice)
Sep-28-26 07:30AM	Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 (PR Newswire)
Sep-11-26 07:17AM	Biohavens epilepsy drug hit with FDA clinical hold (Clinical Trials Arena)
Sep-10-26 02:14PM	Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. (Barrons.com) -14.73%
12:13PM	FDA places partial hold on Biohavens epilepsy drug (BioPharma Dive)
10:10AM	Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials (InvestorsHub)
09:45AM	Loading…
09:45AM	BHVN Stock Crashes 10% Why Did FDA Put Biohavens Epilepsy Trial On Partial Hold? (Stocktwits)
Sep-08-26 06:53AM	Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target (InvestorsHub) -6.18%
Aug-27-26 05:49PM	Slate Medicines Starts Migraine Treatment Study (Exec Edge)
10:40AM	SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race (Pharmaceutical Technology)
Aug-26-26 01:00PM	BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout (Stocktwits) +17.87%
08:28AM	Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal (InvestorsHub)
07:17AM	Biohaven trades cash for upside with $795M epilepsy drug deal (BioPharma Dive)
02:36AM	Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy (PR Newswire)
Aug-25-26 04:41PM	Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University (PR Newswire) +5.12%
Aug-10-26 04:02PM	Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results (PR Newswire)
Aug-06-26 07:00AM	Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors (PR Newswire) +5.80%
Jul-27-26 07:00AM	Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million (PR Newswire)
Jul-20-26 07:30AM	Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload (PR Newswire)
Jul-10-26 04:04AM	ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership (BioPharma Dive) -7.39%
Jul-09-26 05:00PM	Biohaven Announces Scientific Leadership Transitions (PR Newswire)
08:12PM	Loading…
Jul-08-26 08:12PM	BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts (Stocktwits) +7.01%
Jun-30-26 07:30AM	Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator (PR Newswire)
04:19AM	Why Is BHVN Stock Falling Premarket? (Stocktwits)
Jun-29-26 12:01PM	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com) -5.56%
07:30AM	Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease (PR Newswire)
Jun-18-26 08:30AM	Pfizer CFO Dave Denton stepping down in August 2026 (Quartz)
Jun-12-26 05:31AM	Rapport fully prepared to launch seizure drug solo, CEO says (BioPharma Dive)
Jun-01-26 07:30AM	Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation (PR Newswire)
May-27-26 07:30AM	Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy (PR Newswire) +12.12%
May-26-26 07:30AM	Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile (PR Newswire) +6.56%
May-04-26 04:02PM	Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results (PR Newswire) +5.30%
Mar-19-26 07:30AM	Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment (PR Newswire)
Mar-09-26 11:47AM	What's Going On With Biohaven Stock On Monday? (Benzinga)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
Mar-02-26 04:05PM	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results (PR Newswire) -9.65%
Feb-28-26 10:08AM	Biohaven Ltd. (BHVN): A Bull Case Theory (Insider Monkey)
Feb-10-26 09:40AM	Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-09-26 09:55AM	Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect? (Zacks) +10.17%
Feb-06-26 08:07AM	Here Are Fridays Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More (24/7 Wall St.) +7.81%
Jan-22-26 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks) +6.92%
Jan-14-26 09:48PM	Biohaven (BHVN) Stock Is Trending Overnight - Here's What You Should Know (Benzinga) +6.65%
Jan-12-26 11:15AM	Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +6.57%
Jan-07-26 07:00AM	Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 (PR Newswire) +22.04%
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
02:14PM	These Stocks Are Moving the Most Today: Nvidia, Apple, Tesla, Coupang, Micron, Lam Research, Newmont, Moderna, and More (Barrons.com)
10:25AM	Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial (Schaeffer's Research)
08:18AM	Biohaven sinks on disappointing trial and other early movers (MarketWatch)
07:39AM	These Stocks Are Moving the Most Today: Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More (Barrons.com)
06:07AM	S&P Futures Muted in Thin Post-Christmas Trade (Barchart)
04:27AM	Stock Market Today: Dow, S&P 500 set to hover near fresh records in thin holiday trading; silver, gold and copper rally continue, industrial metals also climb (MarketWatch)
Dec-24-25 01:00PM	Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder (PR Newswire)
09:55AM	Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know (Zacks)
Dec-19-25 12:00PM	Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-11-25 07:00AM	Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress (PR Newswire) +7.92%
Dec-04-25 09:55AM	How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% (Zacks) +5.37%
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 08:40AM	Jim Cramer on Biohaven: "The Stock Seems Very Low to Me" (Insider Monkey)
Nov-20-25 12:37PM	Biohaven Insiders Bet $33 Million on a Turnaround (MarketBeat)
Nov-18-25 09:45AM	Carl Icahn Makes Another Huge Insider Purchase (24/7 Wall St.) +14.27%
Nov-16-25 10:13PM	William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth (Insider Monkey)
Nov-13-25 04:05PM	Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M (PR Newswire)
Nov-12-25 07:15AM	Biohaven Announces Pricing of $175 Million Public Offering of Common Shares (PR Newswire) -6.69%
Nov-11-25 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire) +9.37%
Nov-10-25 06:58AM	Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.69%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -40.22%
06:59AM	Knocked back by the FDA, Biohaven turns to major cost cuts (BioPharma Dive)
Nov-04-25 08:06PM	FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia (PR Newswire) -6.06%
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly) +8.97%
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
Sep-09-25 04:14PM	Shareholders of Biohaven Ltd. (BHVN): Protect Your Rights Before September 12, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-03-25 05:48PM	Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN (Business Wire)
12:01PM	Biohavens rare disease drug is ready to ship on Day 1 following FDA approval (BioPharma Dive)
Aug-22-25 06:18PM	Why Biohaven Stock Zoomed More Than 6% Higher Today (Motley Fool) +6.34%
04:15PM	Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News? (Investor's Business Daily)
09:14AM	Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting (Benzinga)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
Aug-18-25 04:55PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 12, 2025 - Biohaven Ltd. (BHVN) (Newsfile)
Aug-17-25 11:41PM	Leerink Lowers Biohaven (BHVN) PT to $50 Following Q2 Report, Acknowledging Positive Pipeline Progress (Insider Monkey)
Aug-11-25 07:00AM	Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -9.02%
Aug-08-25 04:23PM	Biohaven Ltd. (BHVN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 12, 2025 (Newsfile)
Jul-29-25 08:45AM	Shareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN (PR Newswire)
Jul-21-25 04:37PM	Did You Lose Money on Biohaven Ltd. (BHVN)? Levi & Korsinsky Urges Investors to Act Before September 12, 2025 (Newsfile)
Jul-15-25 08:59AM	Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform (Insider Monkey) -6.55%
Jun-10-25 02:00PM	Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development (GlobeNewswire)
May-29-25 07:01AM	Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor (PR Newswire)
12:16AM	Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy (Insider Monkey)
May-28-25 03:00PM	Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN) (PR Newswire)
07:30AM	Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gentile Kimberly	SVP, Clinical Operations	Jan 05 '26	Option Exercise	0.00	3,750	0	101,513	Jan 07 09:34 PM
Buten Matthew	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	4,250	0	198,246	Jan 07 09:33 PM
Coric Vlad	Chief Executive Officer	Jan 05 '26	Option Exercise	0.00	14,250	0	1,811,398	Jan 07 09:32 PM
Car Bruce	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	4,750	0	10,096	Jan 07 09:32 PM
Clark George C.	VP, Chief Accounting Officer	Jan 05 '26	Option Exercise	0.00	2,500	0	68,095	Jan 07 09:31 PM
Clark George C.	VP, Chief Accounting Officer	Nov 17 '25	Buy	8.52	17,000	144,770	20,000	Nov 18 07:29 AM
Bailey Gregory	Director	Nov 13 '25	Buy	7.50	400,000	3,000,000	2,020,071	Nov 17 07:31 AM
CHILDS JOHN W	Director	Nov 13 '25	Buy	7.50	3,333,333	24,999,998	5,653,904	Nov 17 07:30 AM
Coric Vlad	Chief Executive Officer	Nov 13 '25	Buy	7.50	666,666	4,999,995	1,195,275	Nov 17 07:30 AM

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Chairman & CEODr. Vladimir Coric M.D.

Chief Financial OfficerMr. Matthew Buten

Senior Vice President of Clinical OperationsMs. Kimberly Gentile

DACVPDr. Bruce D. Car D.V.M.

Senior Director of Regulatory Affairs & OperationsMs. Deb Young

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BHVN

Biohaven Ltd

Upgrade your Finviz experience